MarketPeel
Insider Trading Intelligence
Pricing
…
WW

William D. Waddill

PTGX
DIRECTOR · PROTAGONIST THERAPEUTICS, INC · CIK 0001553338
FILING MIX · LIFETIME47%/53%
BUYS
34
SELLS
39
TOTAL VALUE
$12.27M
COMPANIES
3
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
135,339
AVG SELL PX
$61.67
TRADE KIND
SHOWING 73 / 73
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
24 backtested trades · 8 horizons · 22 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by William D. Waddill, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d24+62.50%-2.92%+0.63%-3.55%-3.79%—
14d24+79.17%-5.68%+0.50%-6.18%-8.54%—
30d24+70.83%-4.07%+2.01%-6.08%-7.96%—
60d24+54.17%-2.52%+2.12%-4.63%-6.89%—
90d24+70.83%-6.74%+3.63%-10.37%-13.39%—
180d24(1 pending)+34.78%+5.16%+7.65%-2.49%-3.88%—
1y24(8 pending)+43.75%+31.03%+17.54%+13.49%+0.63%—
2y24(13 pending)+63.64%+17.50%+26.98%-9.48%-55.55%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PTGX · 7,825 shares · as of Jun 23, 2026
07,50015,00022,50030,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 34 buys / 39 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
9,000$117.94$1.06M7,825Jun 23, 2026Jun 25, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
9,000——0Jun 23, 2026Jun 25, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
9,000$16.54$148.9K16,825Jun 23, 2026Jun 25, 2026 ↗View →
ANNX
ANNEXON, INC.
PURCHASEGRANT
Stock grant
65,000——65,000Jun 11, 2026Jun 15, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
6,000——9,000Jun 10, 2026Jun 11, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
3,000$11.80$35.4K10,825Jun 10, 2026Jun 11, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
9,000$107.68$969.1K7,825Jun 10, 2026Jun 11, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
6,000$16.54$99.2K16,825Jun 10, 2026Jun 11, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
3,000——0Jun 10, 2026Jun 11, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
9,000$99.64$896.8K7,825May 29, 2026Jun 1, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
9,000$11.80$106.2K16,825May 29, 2026Jun 1, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
9,000——3,000May 29, 2026Jun 1, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
20,000$83.68$1.67M7,825Feb 6, 2026Feb 6, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
20,000$8.31$166.2K27,825Feb 6, 2026Feb 6, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
20,000——0Feb 6, 2026Feb 6, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
3,762——3,762Jan 2, 2026Jan 6, 2026 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
2,695——7,825Jan 2, 2026Jan 6, 2026 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
500$68.53$34.3K56,563Dec 19, 2025Dec 23, 2025 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,451$68.01$370.7K57,063Dec 19, 2025Dec 23, 2025 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,416$66.66$161.1K62,514Dec 19, 2025Dec 23, 2025 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,819——64,930Dec 16, 2025Dec 18, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
12,000$6.98$83.8K17,130Oct 10, 2025Oct 14, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
12,000——0Oct 10, 2025Oct 14, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
4,000$69.25$277.0K13,130Oct 10, 2025Oct 14, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
8,000$87.81$702.5K5,130Oct 10, 2025Oct 14, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
4,000$64.25$257.0K5,130Sep 22, 2025Sep 24, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
4,000$59.25$237.0K9,130Aug 27, 2025Aug 29, 2025 ↗View →
ANNX
ANNEXON, INC.
PURCHASEGRANT
Stock grant
55,000——55,000Jun 5, 2025Jun 9, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
4,000$54.25$217.0K13,130Mar 17, 2025Mar 19, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
5,130——17,130Jan 2, 2025Jan 6, 2025 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
6,584——6,584Jan 2, 2025Jan 6, 2025 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
16,733$22.99$384.7K57,111Dec 18, 2024Dec 20, 2024 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,747$22.04$82.6K40,378Dec 17, 2024Dec 18, 2024 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,748$21.90$82.1K44,125Dec 16, 2024Dec 18, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
8,000——0Sep 10, 2024Sep 12, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
8,000$45.00$360.0K12,000Sep 10, 2024Sep 12, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
8,000$12.88$103.0K20,000Sep 10, 2024Sep 12, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
8,000$40.00$320.0K12,000Jul 24, 2024Jul 26, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
8,000——8,000Jul 24, 2024Jul 26, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
8,000$12.88$103.0K20,000Jul 24, 2024Jul 26, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
8,000——16,000Jun 7, 2024Jun 11, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
8,000$35.00$280.0K12,000Jun 7, 2024Jun 11, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
8,000$12.88$103.0K20,000Jun 7, 2024Jun 11, 2024 ↗View →
ANNX
ANNEXON, INC.
PURCHASEGRANT
Stock grant
44,000——44,000Jun 5, 2024Jun 7, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
12,975$6.09$79.0K24,975Mar 1, 2024Mar 1, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
12,975——0Mar 1, 2024Mar 1, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE10b5-1
10b5-1 plan
12,975$31.34$406.6K12,000Mar 1, 2024Mar 1, 2024 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,300$38.59$50.2K47,870Jan 11, 2024Jan 11, 2024 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,634$37.81$99.6K49,170Jan 11, 2024Jan 11, 2024 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
25,700——25,700Jan 2, 2024Jan 4, 2024 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
14,987$25.41$380.8K51,804Dec 15, 2023Dec 18, 2023 ↗View →
ANNX
ANNEXON, INC.
PURCHASEGRANT
Stock grant
24,000——24,000Jun 8, 2023Jun 12, 2023 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
30,000——30,000Jan 16, 2023Jan 18, 2023 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,867——36,817Jan 10, 2023Jan 11, 2023 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,593——4,593Jan 10, 2023Jan 11, 2023 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
3,200$30.00$96.0K28,950Jan 9, 2023Jan 11, 2023 ↗View →
ANNX
ANNEXON, INC.
PURCHASEGRANT
Stock grant
24,000——24,000Jun 9, 2022Jun 13, 2022 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
20,000——20,000May 26, 2022May 27, 2022 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
SALE
12,000——0May 3, 2022May 4, 2022 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASE
12,000$8.59$103.1K12,000May 3, 2022May 4, 2022 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,400——32,150Jan 7, 2022Jan 7, 2022 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
272$66.25$18.0K25,750Jan 3, 2022Jan 4, 2022 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
2,128$65.01$138.3K26,022Jan 3, 2022Jan 4, 2022 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
2,100$64.23$134.9K28,150Jan 3, 2022Jan 4, 2022 ↗View →
ANNX
ANNEXON, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Aug 12, 2021Aug 16, 2021 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
18,000——18,000May 27, 2021May 28, 2021 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
3,750$76.08$285.3K30,250Jan 4, 2021Jan 5, 2021 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,000——34,000Jan 1, 2021Jan 5, 2021 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
1,200$68.50$82.2K26,800Dec 10, 2020Dec 11, 2020 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
1,800$73.10$131.6K25,000Dec 10, 2020Dec 11, 2020 ↗View →
PTGX
PROTAGONIST THERAPEUTICS, INC
PURCHASEGRANT
Stock grant
15,000——15,000May 28, 2020May 29, 2020 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
SALE
26,000$36.54$950.0K28,000May 11, 2020May 13, 2020 ↗View →
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
7,500——54,000Jan 1, 2020Jan 3, 2020 ↗View →
Other insiders · PTGX
Loading peer insiders…
About this filer
CIK 0001553338
ROLE
Director
PRIMARY
PTGX
COMPANIES
3
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001553338DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback